PICOLINAMIDE COMPOUNDS

The present disclosure is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and solvates of the salt thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing...

Full description

Saved in:
Bibliographic Details
Main Authors POWELL, David Andrew, SEIDERS, Thomas Jon, ROPPE, Jeffrey Roger, JACINTHO, Jason Duarte, DING, Jinyue, SHENG, Tao
Format Patent
LanguageEnglish
French
Published 25.04.2019
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:The present disclosure is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and solvates of the salt thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. Compounds of Formula (I), or pharmaceutically acceptable salts thereof, are inhibitors of IDO. La présente invention concerne de nouveaux composés de formule (I) et des sels pharmaceutiquement acceptables, des solvates, des solvates du sel de ceux-ci, utiles dans la prévention (par exemple, retarder l'apparition ou réduire le risque de développement) et le traitement (par exemple, maîtriser, soulager ou ralentir la progression) du cancer, y compris le glioblastome, le cancer de l'os, le cancer de la tête et du cou, le mélanome, le carcinome basocellulaire, le carcinome des cellules squameuses, l'adénocarcinome, le cancer buccal, le cancer de l'œsophage, le cancer gastrique, le cancer du côlon, le cancer de la vessie, le carcinome hépatocellulaire, le carcinome des cellules rénales, le cancer du pancréas, le cancer de l'ovaire, le cancer du col de l'utérus, le cancer du poumon, le cancer du sein et le cancer de la prostate. Les composés de formule (I), ou leurs sels pharmaceutiquement acceptables, sont des inhibiteurs de l'IDO.
Bibliography:Application Number: WO2018US56539